EUVIMEDOpdag EUVIMED
EditorialOpen access

The benefits of combined treatment with corticosteroids and longacting beta agonists

Dave Singh

International Journal of COPD · 2006

DOI: 10.2147/copd.2006.1.3.207 ↗

At a glance

Editorial in International Journal of COPD, 2006. Written by Dave Singh. Major MEDLINE topics: Delayed-Action Preparations, Drug Therapy, Combination. 10 references. The full text is freely available in PubMed Central.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

The benefits of combined treatment with corticosteroids and longacting beta agonistsGuidelines for the treatment of COPD recommend that long-acting beta agonists (LABA) are used initially to maximize lung function and relieve symptoms in patients with mild to moderate disease who are being treated with short-acting bronchodilators (www.goldcopd.com).Inhaled corticosteroid (ICS) therapy reduces exacerbation rates in patients with more severe disease (Burge et al 2000), and so guidelines recommend that these drugs are used for this purpose primarily in patients with FEV 1

Subjects

MeSH terms (MEDLINE)

Delayed-Action PreparationsDrug Therapy, CombinationAdministration, InhalationAdrenal Cortex HormonesAdrenergic beta-AgonistsHumansPulmonary Disease, Chronic Obstructive

Substances

Adrenal Cortex HormonesAdrenergic beta-AgonistsDelayed-Action Preparations

Cite

APA

Singh, D. (2006). The benefits of combined treatment with corticosteroids and longacting beta agonists. International Journal of COPD. https://doi.org/10.2147/copd.2006.1.3.207

Vancouver

Singh D. The benefits of combined treatment with corticosteroids and longacting beta agonists. International Journal of COPD. 2006. doi:10.2147/copd.2006.1.3.207

BibTeX
@article{Singh2006,
  author = {Singh, Dave},
  title = {The benefits of combined treatment with corticosteroids and longacting beta agonists},
  journal = {International Journal of COPD},
  year = {2006},
  doi = {10.2147/copd.2006.1.3.207}
}
Start for free →